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LETTER TO THE EDITOR
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Haemodiafiltration (HDF) and haemodialysis (HD) are both wellestablished treatment methods worldwide. They are widely
used as maintenance renal replacement therapy (RRT) for
patients suffering from kidney failure, i.e. glomerular filtration
rate below 15 mL/min/1.73 m2 [1].
HD was first established in 1944 by Willem Kolff [2] and
has since become the standard treatment globally for end-stage
renal disease (ESRD) patients [3]. Over the years, this treatment
has progressed, developed and evolved into HDF, a different
treatment opportunity for the same patient cohort.
Better outcomes have been reported for HDF than for HD [4].
HDF has also been described as being increasingly used worldwide and a promising alternative to HD [5].
In Australia, the first satellite dialysis clinics were established
in 1977, providing HD to the wider community [6]. However, for
over 10 years now, it has been asked whether HDF should be
the preferred treatment method for ESRD patients. Data from
the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) showed that in 2005 only 2.65% of all prevalent
ESRD patients received HDF, with conventional HD performed
in 48.4% of these patients [7]. The same authors proposed that
HDF should be more frequently used, specifically if HD time and
rate of HD sessions could not be increased. A 2018 study by
Locatelli et al. [8] indicated that in Europe, 18% of all dialysis patients received online HDF as their chosen form of treatment.
Concurrently HDF was used in Japan in only 8% of all HD patients and was not being used at all in the USA. This may have
been due to variances in regulatory approval processes for the
online HDF method. A recent study by Mac et al. [9] described
factors that may have affected the use of HDF over HD but also

reported a steady increase in the use of HDF between 2000 and
2014 in Australia and New Zealand.
Today, this has changed significantly and the most recent ANZDATA figures from December 2019 indicate that HDF
has become the dominant treatment over HD, with 68.2%
of all patients on RRT receiving HDF in Western Australia
(WA), 41.4% in South Australia (SA) and 46.5% in Queensland
(QLD) [10]. This resulted in a total percentage of 35.6% for
the whole of Australia in 2018 and 20.5% for New Zealand
for HDF of all RRT treatments, which is certainly a new
milestone.
HDF is distinctively different from HD and uses a different
technical approach, though is still classified as an RRT just like
our old friend—the traditional method of HD. It is our belief that
we need to begin changing our terminology when we talk about
RRT in terms of HD, as HDF may soon become the common standard treatment method. It may also be necessary that we consider relabelling our hospitals and satellite dialysis clinics more
correctly to ‘Haemodiafiltration Clinics’. For some experts in the
renal community, it may appear overly pedantic that we would
suggest relabelling, but we believe that a genuine argument can
now be made for the need for a change of terminology, at least
for WA. If future uptake of HDF continues to remain as popular as it is today, this will also become applicable for reporting
organizations such as ANZDATA, which currently still publish
under the heading ‘Haemodialysis’ for their annual reports for
both Australia and New Zealand. This also applies to the European Renal Association (ERA), which is still reporting kidney
replacement therapy just as HD [11].
Call the sign-makers…!
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